MBX Biosciences, Inc. Common Stock (MBX) NASDAQ
40.97
+6.255(+18.02%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
40.97
+6.255(+18.02%)
Currency In USD
Address
11711 N. Meridian Street
Carmel, IN 46032
United States of America (the)
Phone
(317) 659-0200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
43
First IPO Date
January 14, 2000
| Name | Title | Pay | Year Born |
| Peter Kent Hawryluk | Chief Executive Officer, President & Director | 992,775 | 1969 |
| Steven L. Hoerter | Executive Chairperson | 40,477 | 1971 |
| Richard Bartram | Chief Financial Officer | 642,001 | 1982 |
| Salomon Azoulay | Chief Medical Officer | 734,944 | 1958 |
| Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | 0 | N/A |
| Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | 0 | N/A |
| Michelle Graham | Chief Human Resources Officer | 0 | 1967 |
| John W. Smither | Interim Chief Financial Officer | 0 | 1953 |
| Mark Hope | Senior Vice President of Regulatory & Quality | 0 | N/A |
| Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Karen Basbaum | Chief Business Officer | 0 | N/A |
| Andreas Moraitis | Senior Vice President of Clinical Development | 0 | N/A |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.